An update on aspirin in the primary prevention of cardiovascular disease.

@article{Eidelman2003AnUO,
  title={An update on aspirin in the primary prevention of cardiovascular disease.},
  author={Rachel S. Eidelman and Patricia R. Hebert and Steven M. Weisman and Charles H Hennekens},
  journal={Archives of internal medicine},
  year={2003},
  volume={163 17},
  pages={
          2006-10
        }
}
BACKGROUND In 1988, the aspirin component of the Physicians' Health Study, a randomized, double-blind, placebo-controlled trial of 22 071 apparently healthy men was terminated early, due principally to a statistically extreme (P<.00001) 44% reduction in the risk of a first myocardial infarction (MI). The Cardio-Renal Drugs Advisory Committee recommended that the US Food and Drug Administration approve professional labeling of aspirin to prevent first MI. The agency did not act on this… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 75 CITATIONS

Pathophysiologic, rather than laboratory-defined resistance drives aspirin failure in ischemic stroke.

  • Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
  • 2015
VIEW 1 EXCERPT
CITES BACKGROUND

FILTER CITATIONS BY YEAR

2003
2019

CITATION STATISTICS

  • 1 Highly Influenced Citations

  • Averaged 2 Citations per year over the last 3 years

References

Publications referenced by this paper.
SHOWING 1-10 OF 20 REFERENCES

Additive benefits of pravastatin and aspirin to reduce risks of cardiovascular disease

CH Hennekens, F Sacks, A Tomkin
  • Arch Intern Med. In press. (REPRINTED) ARCH INTERN MED/
  • 2003
VIEW 1 EXCERPT

Additive effects of aspirin and statins

PR Hebert, MA Pfeffer, CH. Hennekens
  • J Cardiovasc Pharmacol Ther
  • 2002

Similar Papers

Loading similar papers…